Where Will Sonnet BioTherapeutics Holdings, Inc. (SONN) Stock Go Next After It Is Lower By 12.95% in a Week?

Overall market sentiment has been down on Sonnet BioTherapeutics Holdings, Inc. (SONN) stock lately. SONN receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Sonnet BioTherapeutics Holdings, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SONN!

See Full SONN Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With SONN Stock Today?

Sonnet BioTherapeutics Holdings, Inc. (SONN) stock is higher by 2.54% while the S&P 500 has fallen -0.21% as of 10:32 AM on Monday, Nov 13. SONN has gained $0.03 from the previous closing price of $1.18 on volume of 8,892 shares. Over the past year the S&P 500 is up 11.34% while SONN has fallen -95.53%. SONN lost -$64.90 per share in the over the last 12 months.

More About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Click Here to get the full Stock Report for Sonnet BioTherapeutics Holdings, Inc. stock.